For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer.
In this video, Dr. Fred Hirsch discusses options when a patient with EGFR+ NSCLC develops acquired resistance to Osimertinib.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.